Dr Sanjiban Chakrabarty

Associate Professor

Department of Public Health Genomics

CURRENT ACADEMIC ROLE & RESPONSIBILITIES

    Sanjiban Chakrabarty is Associate Professor in the Department of Cell and Molecular Biology at the 沙巴体育 School of Life Sciences.

    He is:

    • Guides doctoral, post-graduate and graduate students for various research projects
    • Involved in molecular diagnostics of genetic disorders

ACADEMIC QUALIFICATIONS

Degree Specialisation Institute Year of passing
PhD Human Genetics School of Life Sciences, MAHE, 沙巴体育 2013

Experience

Institution / Organisation Designation Role Tenure
School of Life Sciences/沙巴体育 Academy of Higher Education Assistant Professor 2013-2022
Molecular Genetics, Erasmus Medical Center, The Netherlands Postdoctoral Fellow 2018-2019
沙巴体育 School of Life Sciences Associate Professor 2022-Present

AREAS OF INTEREST, EXPERTISE AND RESEARCH

Area of Interest

Molecular mechanism of carcinogenesis and chemotherapeutic resistance

Area of Expertise

Genome analysis, mitochondrial biology

Area of 沙巴体育

Nuclear mitochondrial crosstalk in cancer progression and chemotherapeutic resistance

Professional Affiliations & Contributions

  • Executive Committee Member of Society for Mitochondrial 沙巴体育 and Medicine-India
  • Life Member of European Association For Cancer 沙巴体育 (EACR).
  • Life Member of Society of Biological Chemists, India
  • Life Member of Environmental Mutagen Society of India.

Awards and Honors:

Australia awards fellowships program entitled “Metagenomics guided management of drug resistant tuberculosis and HIV: advances in diagnostics” in collaboration with University of Sydney, 2017.

Work Experience

Organisation Role Tenure
Invitrogen Bioservices Business Development Manager 2013-2013
Ecron Acunova (Formerly known as 沙巴体育 Acunova), Bangalore Scientist 2005 - 2007

Targeted sequencing-based analyses of candidate gene variants in ulcerative colitis-associated colorectal neoplasia

2017-18-05 Br J Cancer.

Chakrabarty S, Varghese VK, Sahu P, Jayaram P, Shivakumar BM, Pai CG, Satyamoorthy K.

Epigenomics, Pharmacoepigenomics, and Personalized Medicine in Cervical Cancer

2017-19-05 Public Health Genomics

Kabekkodu SP, Chakrabarty S, Ghosh S, Brand A, Satyamoorthy K.

Aberrant gene-specific DNA methylation signature analysis in cervical cancer

2017-01-03 Tumour Biol

Bhat S, Kabekkodu SP, Varghese VK, Chakrabarty S, Mallya SP, Rotti H, Pandey D, Kushtagi P, Satyamoorthy K

DNA methylation detection at single base resolution using targeted next generation bisulfite sequencing and cross validation using capillary sequencing

2016-01-12 Gene

Bhat S, Mallya S, Varghese VK, Jayaram P, Chakrabarty S, Joshi KS, Nesari TM, Satyamoorthy K

Spastizin mutation in hereditary spastic paraplegia with thin corpus callosum

2016-01-08 J Neurol

Chakrabarty S, Vijayakumar N, Radhakrishnan K, Satyamoorthy K

Comparative analysis of copy number variations in ulcerative colitis associated and sporadic colorectal neoplasia

2016-01-04 BMC Cancer

Shivakumar BM, Chakrabarty S, Rotti H, Seenappa V, Rao L, Geetha V, Tantry BV, Kini H, Dharamsi R, Pai CG, Satyamoorthy K

Perspectives on Translational Genomics and Public Health in India

2016-01-02 Public Health Genomics

Chakrabarty S, Kabekkodu SP, Brand A, Satyamoorthy K

Genome Sequence of a Burkholderia pseudomallei Clinical Isolate from a Patient with Community-Acquired Pneumonia and Septicemia

2015-01-08 Genome Announc

Mukhopadhyay C, Vandana KE, Chaitanya TA, Shaw T, Bhat HV, Chakrabarty S, Paul B, Mallya S, Murali TS, Satyamoorthy K

Mitochondrial biology: From molecules to diseases

2015-01-09 Mitochondrion

Kabekkodu SP, Chakrabarty S, Shukla V, Varghese VK, Singh KK, Thangaraj K, Satyamoorthy K

DNA methylation analysis of phenotype specific stratified Indian population

2015-01-05 J Transl Med

Rotti H, Mallya S, Kabekkodu SP, Chakrabarty S, Bhale S, Bharadwaj R, Bhat BK, Dedge AP, Dhumal VR, Gangadharan GG, Gopinath PM, Govindaraj P, Joshi KS, Kondaiah P, Nair S, Nair SN, Nayak J, Prasanna BV, Shintre P, Sule M, Thangaraj K, Patwardhan B, Valiathan MV, Satyamoorthy K

Copy number variations are progressively associated with the pathogenesis of colorectal cancer in ulcerative colitis

2015-01-01 World J Gastroenterol

Shivakumar BM, Rotti H, Vasudevan TG, Balakrishnan A, Chakrabarty S, Bhat G, Rao L, Pai CG, Satyamoorthy K

Upregulation of TFAM and mitochondria copy number in human lymphoblastoid cells

2014-01-03 Mitochondrion

Chakrabarty S, D'Souza RR, Kabekkodu SP, Gopinath PM, Rossignol R, Satyamoorthy K

Comprehensive DNA copy number profile and BAC library construction of an Indian individual

2012-01-06 Gene

Chakrabarty S, D'Souza RR, Bellampalli R, Rotti H, Saadi AV, Gopinath PM, Acharya RV, Govindaraj P, Thangaraj K, Satyamoorthy K

Methylation markers: a potential force driving cancer diagnostics forward

2011-03-06 Oncol Res

Khandige S, Shanbhogue VV, Chakrabarty S, Satyamoorthy K

Antioxidants and lipid peroxidation in gestational diabetes--a preliminary study

2008-01-04 Indian J Physiol Pharmacol

Dey P, Gupta P, Acharya NK, Rao SN, Ray S, Chakrabarty S, Ramprasad S, Kurian TA, Mawroh A, Kundu A, Bhaktha G, Joseph CP, Kumar P, Rai L, Rao A

Full Publications List

2018-01-01

Implication of TFAM gene mutations in neurodegenerative disorders

2012-01-01 Anush Rajendran

PG, MSc Medical Biotechnology, 2012-2014. Identification and evaluation of structural changes in TFAM gene in neurodegenerative disorders.

Evaluation of mitochondrial anterograde and retrograde signaling in breast cancer

Akhilaja Pratyusha

Identification of Molecular Signatures in Patients with High Risk of Developing Ulcerative Colitis Associated Colorectal Neoplasia

Pranoy Sahu

    SOLS, KMC researchers identify colorectal cancer causing mutations

    2017-07-06

    沙巴体育ers from the School of Life Sciences (SOLS) and Kasturba Medical College, 沙巴体育 University, have identified cancer causing mutations in long standing ulcerative colitis subjects at risk of progressing into colorectal cancer. They have identified cancer causing mutations in new as well as previously identified oncogenes and tumor suppressor genes. The mutations identified in the study can be used as marker for early diagnosis of ulcerative colitis associated colorectal cancer. The finding of the study is published in Nature Publishing Group journal British Journal of Cancer entitled "Targeted sequencing based analyses of candidate gene variants in ulcerative colitis-associated colorectal neoplasia". SOLS has been working in the field of cancer biomarker discovery, disease modelling and targeted drug delivery for the past several years, says its Director, Dr K. Satyamoorthy. He said: As there is an increased incidence of ulcerative colitis in India due to altered food habits, increased awareness, surveillance and availability of better diagnosis, it is important that early diagnosis of patients who are at risk of developing colorectal cancer is of paramount interest". Dr. Satyamoorthy who also led the investigations said the major challenge in the study was long-period of follow up required to monitor the patients with the ulcerative colitis and reluctance of the patients to undergo colonoscopy. Innovative discoveries such as this can lead to better management of individuals with the disease for early detection and personalized care". While congratulating the researchers Dr. H. Vinod Bhat, Vice Chancellor, 沙巴体育 University said the University is supporting molecular genetics programme as there is plenty to discover to the benefit of patients. 沙巴体育 University is in unique environment that researchers, clinical practitioners and public health experts can work together to bring about change in the society on how the diseases are managed in individuals". Ulcerative colitis is a chronic inflammatory bowel condition with clinical symptoms of ulceration and bleeding of inner lining of colon. The age of onset for ulcerative colitis varies between 30 to 50 years. Ulcerative colitis subjects with more than seven years of pancolitis or more than 10 years of left sided colitis, experience a higher incidence of colorectal cancer than the rest of the population. Dr. Sanjiban Chakrabarty, lead author of the manuscript said the DNA mutations discovered in the study could distinguish early dysplastic changes in high risk ulcerative colitis and has the potential to predict an adverse outcome." Lead clinical investigator Dr. Ganesh Pai said the results of the studies are important in view of the rising incidence of both ulcerative colitis and colorectal cancer in the Asia Pacific in recent years. The results can help to better understand the development of colorectal cancer in ulcerative colitis, to develop tests for early diagnosis and to possibly select the best treatment strategies for subgroups of patients in the future"